Proteus in the World of Proteins: Conformational Changes in Protein Kinases
暂无分享,去创建一个
Daniel Rauh | D. Rauh | Matthäus Getlik | André Richters | M. Rabiller | Matthäus Getlik | S. Klüter | A. Richters | Sandra Tückmantel | J. Simard | Jeffrey R Simard | Matthias Rabiller | Sabine Klüter | Sandra Tückmantel
[1] G. Superti-Furga,et al. Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase , 2003, Cell.
[2] S. Harrison,et al. Crystal structures of c-Src reveal features of its autoinhibitory mechanism. , 1999, Molecular cell.
[3] F. Hobbs,et al. Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase* , 1998, The Journal of Biological Chemistry.
[4] Stephen K Burley,et al. A Novel Mode of Gleevec Binding Is Revealed by the Structure of Spleen Tyrosine Kinase* , 2004, Journal of Biological Chemistry.
[5] J. Mestan,et al. Allosteric inhibitors of Bcr-abl–dependent cell proliferation , 2006, Nature chemical biology.
[6] Sung-Hou Kim,et al. Crystal structure of cyclin-dependent kinase 2 , 1993, Nature.
[7] Chung F. Wong,et al. Conformational selection of protein kinase A revealed by flexible‐ligand flexible‐protein docking , 2009, J. Comput. Chem..
[8] S. Kim,et al. High-resolution crystal structures of human cyclin-dependent kinase 2 with and without ATP: bound waters and natural ligand as guides for inhibitor design. , 1996, Journal of medicinal chemistry.
[9] R. Abagyan,et al. Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states. , 2008, Journal of medicinal chemistry.
[10] John Kuriyan,et al. Crystal structure of the Src family tyrosine kinase Hck , 1997, Nature.
[11] R. Morphy. Selectively nonselective kinase inhibition: striking the right balance. , 2010, Journal of medicinal chemistry.
[12] H. Harada,et al. Interaction between Hck and HIV-1 Nef negatively regulates cell surface expression of M-CSF receptor. , 2008, Blood.
[13] J. Adams. Activation loop phosphorylation and catalysis in protein kinases: is there functional evidence for the autoinhibitor model? , 2003, Biochemistry.
[14] K. Ferguson,et al. Structure-based view of epidermal growth factor receptor regulation. , 2008, Annual review of biophysics.
[15] Helmut Grubmüller,et al. Mechanoenzymatics of titin kinase , 2008, Proceedings of the National Academy of Sciences.
[16] A. Reith,et al. The Structure of Phosphorylated GSK-3β Complexed with a Peptide, FRATtide, that Inhibits β-Catenin Phosphorylation , 2001 .
[17] Daniel Rauh,et al. A new screening assay for allosteric inhibitors of cSrc. , 2009, Nature chemical biology.
[18] Federico Gago,et al. In silico activation of Src tyrosine kinase reveals the molecular basis for intramolecular autophosphorylation. , 2004, Journal of molecular graphics & modelling.
[19] Susan S. Taylor,et al. Crystal structures of the myristylated catalytic subunit of cAMP‐dependent protein kinase reveal open and closed conformations , 1993, Protein science : a publication of the Protein Society.
[20] L. Johnson,et al. The crystal structure of a phosphorylase kinase peptide substrate complex: kinase substrate recognition , 1997, The EMBO journal.
[21] M. Lamers,et al. Structure of the protein tyrosine kinase domain of C-terminal Src kinase (CSK) in complex with staurosporine. , 1999, Journal of molecular biology.
[22] A. Reith,et al. The structure of MSK1 reveals a novel autoinhibitory conformation for a dual kinase protein. , 2004, Structure.
[23] D. Gilliland,et al. Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD. , 2006, Blood.
[24] Susan S. Taylor,et al. Crystal structure of a transition state mimic of the catalytic subunit of cAMP-dependent protein kinase , 2002, Nature Structural Biology.
[25] E. Krebs. Historical perspectives on protein phosphorylation and a classification system for protein kinases. , 1983, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[26] T. Pawson,et al. Structural Basis for Autoinhibition of the EphB2 Receptor Tyrosine Kinase by the Unphosphorylated Juxtamembrane Region , 2001, Cell.
[27] S. Steinberg. Distinctive activation mechanisms and functions for protein kinase Cdelta. , 2004, The Biochemical journal.
[28] Tom Alber,et al. Structure of Mycobacterium tuberculosis PknB supports a universal activation mechanism for Ser/Thr protein kinases , 2003, Nature Structural Biology.
[29] T. Pawson. New impressions of Src and Hck , 1997, Nature.
[30] John Kuriyan,et al. Structural Basis for the Inhibition of Tyrosine Kinase Activity of ZAP-70 , 2007, Cell.
[31] Neil Q. McDonald,et al. Crystal structure of a γ‐herpesvirus cyclin–cdk complex , 2000 .
[32] Benoît Roux,et al. Src Kinase Conformational Activation: Thermodynamics, Pathways, and Mechanisms , 2008, PLoS Comput. Biol..
[33] Kornelia Polyak,et al. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex , 1995, Nature.
[34] J. Warmus,et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition , 2004, Nature Structural &Molecular Biology.
[35] Bairong Shen,et al. Genome wide analysis of pathogenic SH2 domain mutations , 2008, Proteins.
[36] D. Fabbro,et al. The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation. , 2005, Structure.
[37] T. Hunter,et al. The Protein Kinase Complement of the Human Genome , 2002, Science.
[38] E. Baker,et al. Structure and inhibition of the human cell cycle checkpoint kinase, Wee1A kinase: an atypical tyrosine kinase with a key role in CDK1 regulation. , 2005, Structure.
[39] Nguyen-Huu Xuong,et al. Crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with magnesium-ATP and peptide inhibitor , 1993 .
[40] J. Walker,et al. Autoregulation by the juxtamembrane region of the human ephrin receptor tyrosine kinase A3 (EphA3). , 2008, Structure.
[41] Elizabeth J. Goldsmith,et al. Activation Mechanism of the MAP Kinase ERK2 by Dual Phosphorylation , 1997, Cell.
[42] C. Grütter,et al. Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc. , 2009, Journal of medicinal chemistry.
[43] Hiroto Yamaguchi,et al. Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation , 1996, Nature.
[44] B. Keyt,et al. The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 A resolution: multiple copy flexibility and receptor binding. , 1997, Structure.
[45] T. Pawson,et al. A change in conformational dynamics underlies the activation of Eph receptor tyrosine kinases , 2006, The EMBO journal.
[46] Alex Matter,et al. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug , 2002, Nature Reviews Drug Discovery.
[47] M. Teplova,et al. Crystal structures of the catalytic domain of human protein kinase associated with apoptosis and tumor suppression , 2001, Nature Structural Biology.
[48] John Kuriyan,et al. Mechanism for Activation of the EGF Receptor Catalytic Domain by the Juxtamembrane Segment , 2009, Cell.
[49] J. Kuriyan,et al. Activation of the Sire-family tyrosine kinase Hck by SH3 domain displacement , 1997, Nature.
[50] R. Knegtel,et al. Crystal Structure of Aurora-2, an Oncogenic Serine/Threonine Kinase* , 2002, The Journal of Biological Chemistry.
[51] A. Kral,et al. Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors , 2022 .
[52] G. Alton,et al. Characterization of the CHK1 allosteric inhibitor binding site. , 2009, Biochemistry.
[53] Chao Zhang,et al. The unfolded protein response signals through high-order assembly of Ire1 , 2009, Nature.
[54] Sibylle Mittnacht,et al. Trans‐activation of the DNA‐damage signalling protein kinase Chk2 by T‐loop exchange , 2006, The EMBO journal.
[55] A. Wissner,et al. The Development of HKI‐272 and Related Compounds for the Treatment of Cancer , 2008, Archiv der Pharmazie.
[56] E. Estey,et al. Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML). , 2005, Blood.
[57] Daniel Rauh,et al. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors. , 2009, Journal of the American Chemical Society.
[58] H. Jäckle,et al. Mitogen‐activated protein kinases interacting kinases are autoinhibited by a reprogrammed activation segment , 2006, The EMBO journal.
[59] D. Koshland. Application of a Theory of Enzyme Specificity to Protein Synthesis. , 1958, Proceedings of the National Academy of Sciences of the United States of America.
[60] A. Pozzi,et al. The juxtamembrane region of the EGF receptor functions as an activation domain. , 2009, Molecular cell.
[61] K. Wilson,et al. Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase* , 2004, Journal of Biological Chemistry.
[62] L. Schmidt,et al. Structural basis of oncogenic activation caused by point mutations in the kinase domain of the MET proto‐oncogene: Modeling studies , 2001, Proteins.
[63] D. Morgan,et al. Protein kinase regulation: insights from crystal structure analysis. , 1994, Current opinion in cell biology.
[64] F. Lu,et al. The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. , 2004, Molecular cell.
[65] N. Gray,et al. N-Myristoylated c-Abl Tyrosine Kinase Localizes to the Endoplasmic Reticulum upon Binding to an Allosteric Inhibitor* , 2009, The Journal of Biological Chemistry.
[66] C. Grütter,et al. Displacement assay for the detection of stabilizers of inactive kinase conformations. , 2010, Journal of Medicinal Chemistry.
[67] P. Parker,et al. PKC maturation is promoted by nucleotide pocket occupation independently of intrinsic kinase activity , 2009, Nature Structural &Molecular Biology.
[68] Martin Peifer,et al. Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation. , 2010, Cancer research.
[69] Chao Zhang,et al. Inhibitor Hijacking of Akt Activation , 2009, Nature chemical biology.
[70] E. P. Kennedy,et al. The enzymatic phosphorylation of proteins. , 1954, The Journal of biological chemistry.
[71] L. Tsai,et al. Structure and Regulation of the CDK5-p25nck5a Complex , 2001 .
[72] L. Johnson. The regulation of protein phosphorylation. , 2009, Biochemical Society transactions.
[73] S. Knapp,et al. Structure of the Human Protein Kinase MPSK1 Reveals an Atypical Activation Loop Architecture , 2008, Structure.
[74] K. Longenecker,et al. Three-dimensional structure of mammalian casein kinase I: molecular basis for phosphate recognition. , 1996, Journal of molecular biology.
[75] C. Grütter,et al. Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR. , 2008, Bioorganic & medicinal chemistry.
[76] P. Jeffrey,et al. Structural basis of cyclin-dependent kinase activation by phosphorylation , 1996, Nature Structural Biology.
[77] B. Keyt,et al. 1H, 13C, and 15N backbone assignment and secondary structure of the receptor‐binding domain of vascular endothelial growth factor , 1997, Protein science : a publication of the Protein Society.
[78] Robert Huber,et al. The Protein Kinase C Inhibitor Bisindolyl Maleimide 2 Binds with Reversed Orientations to Different Conformations of Protein Kinase A* , 2004, Journal of Biological Chemistry.
[79] M. Meyerson,et al. Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML. , 2004, Blood.
[80] B. Druker,et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. , 2000, The Journal of pharmacology and experimental therapeutics.
[81] R. Copeland,et al. Drug–target residence time and its implications for lead optimization , 2007, Nature Reviews Drug Discovery.
[82] Daniel Rauh,et al. High-throughput screening to identify inhibitors which stabilize inactive kinase conformations in p38alpha. , 2009, Journal of the American Chemical Society.
[83] N. Gray,et al. Targeting cancer with small molecule kinase inhibitors , 2009, Nature Reviews Cancer.
[84] L. Johnson,et al. The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases , 1999, Nature Cell Biology.
[85] John Kuriyan,et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). , 2001, Cancer research.
[86] P. Seeburg,et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. , 2000, Science.
[87] L. Johnson,et al. Two structures of the catalytic domain of phosphorylase kinase: an active protein kinase complexed with substrate analogue and product. , 1995, Structure.
[88] Y. Matsuzawa,et al. Constitutive activation of c-kit in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain. , 1996, Blood.
[89] Mark R Player,et al. Crystal Structure of the Tyrosine Kinase Domain of Colony-stimulating Factor-1 Receptor (cFMS) in Complex with Two Inhibitors* , 2006, Journal of Biological Chemistry.
[90] J. Zheng,et al. Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. , 1991, Science.
[91] R. V. van Etten,et al. c-Abl Has High Intrinsic Tyrosine Kinase Activity That Is Stimulated by Mutation of the Src Homology 3 Domain and by Autophosphorylation at Two Distinct Regulatory Tyrosines* , 2000, The Journal of Biological Chemistry.
[92] Harald Schwalbe,et al. NMR characterization of kinase p38 dynamics in free and ligand-bound forms. , 2006, Angewandte Chemie.
[93] Gerard J Kleywegt,et al. Application and limitations of X-ray crystallographic data in structure-based ligand and drug design. , 2003, Angewandte Chemie.
[94] C. Grütter,et al. Fluorophore labeling of the glycine-rich loop as a method of identifying inhibitors that bind to active and inactive kinase conformations. , 2010, Journal of the American Chemical Society.
[95] Satoru Takeuchi,et al. Structure of the Carboxyl-terminal Src Kinase, Csk* , 2002, The Journal of Biological Chemistry.
[96] Susan S. Taylor,et al. Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism , 2006, Proceedings of the National Academy of Sciences.
[97] E. Mandelkow,et al. Structure of the catalytic and ubiquitin-associated domains of the protein kinase MARK/Par-1. , 2006, Structure.
[98] Stefan Knapp,et al. Structure of the Pseudokinase VRK3 Reveals a Degraded Catalytic Site, a Highly Conserved Kinase Fold, and a Putative Regulatory Binding Site , 2009, Structure.
[99] Oliver Hantschel,et al. Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase. , 2006, Molecular cell.
[100] Chung F. Wong,et al. The structure of Sky1p reveals a novel mechanism for constitutive activity , 2001, Nature Structural Biology.
[101] Susan S. Taylor,et al. Evidence for an internal entropy contribution to phosphoryl transfer: a study of domain closure, backbone flexibility, and the catalytic cycle of cAMP-dependent protein kinase. , 2002, Journal of molecular biology.
[102] John Kuriyan,et al. An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor , 2006, Cell.
[103] Allan Wissner,et al. Kinase domain mutations in cancer: implications for small molecule drug design strategies. , 2009, Journal of medicinal chemistry.
[104] Ming-Li Xiang,et al. Detailed conformational dynamics of juxtamembrane region and activation loop in c‐Kit kinase activation process , 2008, Proteins.
[105] G. J. Mulder. Ueber die Zusammensetzung einiger thierischen Substanzen , 1839 .
[106] Chao Zhang,et al. Bypassing a Kinase Activity with an ATP-Competitive Drug , 2003, Science.
[107] Liao Jie-Lou Jeffrey and Andrews C. Robert,et al. Targeting protein multiple conformations: a structure-based strategy for kinase drug design. , 2007 .
[108] P. Dorrestein,et al. A sliding docking interaction is essential for sequential and processive phosphorylation of an SR protein by SRPK1. , 2008, Molecular cell.
[109] G. Müller,et al. Small-molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibition , 2008, Expert opinion on drug discovery.
[110] K. Spiekermann,et al. From Kinases to Cancer: Leakiness, Loss of Autoinhibition and Leukemia , 2006, Cell cycle.
[111] John Kuriyan,et al. A Src-Like Inactive Conformation in the Abl Tyrosine Kinase Domain , 2006, PLoS biology.
[112] G. Müller,et al. Small-molecule inhibitors binding to protein kinases. Part I: exceptions from the traditional pharmacophore approach of type I inhibition , 2008, Expert opinion on drug discovery.
[113] Ron Diskin,et al. A novel lipid binding site formed by the MAP kinase insert in p38 alpha. , 2008, Journal of molecular biology.
[114] L. Johnson. Protein kinase inhibitors: contributions from structure to clinical compounds , 2009, Quarterly Reviews of Biophysics.
[115] L. Pearl,et al. Structural basis for recruitment of glycogen synthase kinase 3β to the axin—APC scaffold complex , 2003, The EMBO journal.
[116] P. Bastiaens,et al. Growth factor-induced MAPK network topology shapes Erk response determining PC-12 cell fate , 2007, Nature Cell Biology.